1-20 of 38 results for subject:Naltrexone
Librarians' tools
- Search time
- 0.261 seconds
- Solr query time
- 0.003 seconds
- Search query
- subject:Naltrexone
- We searched for
- subject_t:Naltrexone OR subject_t:Revia OR subject_ses:11805
Type
House
Session
Year
Department
Member
More
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask His Majesty's Government what assessment they have made of the efficacy of Naltrexone in the treatment of problem gambling.
To ask His Majesty's Government what assessment they have made of the efficacy of Naltrexone in the treatment of problem gambling.
No assessment has been made. The National Institute of Health and Care Excellence is developing a clinical guideline for the treatment of harmful gambling. This will cover psychological and psychosocial interventions as well as pharmacological treatments. The attached document outlines the full scope of the guideline. Publication is expected in spring 2024.
To ask the Secretary of State for Health and Social Care, whether the National Institute for Health and Care Excellence has (a) included and (b) made an assessment of the potential merits of including low dose Naltrexone on its RAPID C-19 programme.
To ask the Secretary of State for Health and Social Care, whether the National Institute for Health and Care Excellence has (a) included and (b) made an assessment of the potential merits of including low dose Naltrexone on its RAPID C-19 programme.
The multi-agency research to access pathway for investigational drugs for COVID-19 (RAPID C-19) was established in 2020 to ensure that treatments for COVID-19 were made available safely to National Health Service (NHS) patients as soon as possible. The initiative has enabled rapid patient access to therapeutics including dexamethasone, remdesivir, tocilizumab and sarilumab and baricitinib, novel antibody treatments such as sotrovimab, and the two oral antivirals molnupiravir and nirmatralvir+ritonavir (Paxlovid).
RAPID C-19 has made no assessment of low dose naltrexone for COVID-19 and its role in reviewing potential COVID-19 treatments is now ending as the NHS moves back to routine commissioning arrangements for these treatments. The National Institute for Health and Care Excellence will therefore appraise new licensed treatments, as appropriate, through its standard Technology Appraisal process and will continue to update its COVID-19 rapid guidelines as the evidence base evolves.
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of including (a) Nalmefene and (b) Naltrexone as part of an alcohol harm reduction strategy.
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of including (a) Nalmefene and (b) Naltrexone as part of an alcohol harm reduction strategy.
The National Institute for Health and Care Excellence (NICE) recommends nalmefene as an option for reducing alcohol consumption for people with alcohol dependence who have a high drinking risk level, without physical withdrawal symptoms and who do not require immediate detoxification. NICE also recommends oral naltrexone for harmful drinkers and people with mild dependence who have not responded to psychological interventions alone, and for people with moderate and severe dependence, following successful withdrawal. NICE recommends that these medications should only be prescribed along with psychosocial intervention.
The Office for Health Improvement and Disparities is developing United Kingdom guidelines for the clinical management of harmful drinking and alcohol dependence, which will include guidance on prescribing nalmefene and naltrexone. Publication of these guidelines is expected later this year.
To ask the Secretary of State for Health and Social Care, whether NICE Guidance CG115 will be updated to reflect studies that conclude that naltrexone is (a) effective at reducing alcohol use and heavy drinking and (b) less effective at maintaining abstinence.
To ask the Secretary of State for Health and Social Care, whether NICE Guidance CG115 will be updated to reflect studies that conclude that naltrexone is (a) effective at reducing alcohol use and heavy drinking and (b) less effective at maintaining abstinence.
Public Health England is working with the Department and the devolved administrations to develop comprehensive United Kingdom guidelines for the clinical management of harmful drinking and alcohol dependence. The guidelines are due to be published in 2021.
The aim of the guidelines is to develop a clear consensus on good practice and help services to implement interventions for alcohol use disorders that are recommended by the National Institute for Health and Care Excellence (NICE). More information on the development of the guidelines can be viewed at the following link:
https://www.gov.uk/government/news/uk-alcohol-clinical-guidelines-development-begins
NICE undertook a surveillance review of its guideline on alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence [CG115] in July 2019, and the decision was made to not update the guideline. While the review found several studies on naltrexone, NICE considered that the new evidence was unlikely to change the current guideline recommendations. Unless presented with new evidence, NICE has no immediate plans to review CG115.
To ask the Secretary of State for Health and Social Care, whether the National Institute of Health and Care Excellence has plans to update is guidance on Naltrexone and opioid antagonists as a treatment for addiction.
To ask the Secretary of State for Health and Social Care, whether the National Institute of Health and Care Excellence has plans to update is guidance on Naltrexone and opioid antagonists as a treatment for addiction.
The National Institute for Health and Care Excellence (NICE) reviewed the evidence on naltrexone for the management of opioid dependence in November 2010 and found nothing new that affects the recommendations in this guidance. In line with NICE’s published procedures, this guidance will be considered for review again if there is new evidence that is likely to change the recommendations.
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the adequacy of supply of (a) buprenorphine, (b) methadone and (c) naltrexone during the covid-19 outbreak.
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the adequacy of supply of (a) buprenorphine, (b) methadone and (c) naltrexone during the covid-19 outbreak.
As part of our concerted national efforts to respond to the COVID-19 outbreak, we are doing everything we can to ensure patients continue to have access safe and effective medicines. Supplies of buprenorphine, methadone and naltrexone continue to remain available.
The Department has well-established procedures to deal with medicine shortages and is working closely with industry, the National Health Service and others in the supply chain to reduce the likelihood of future shortages.
The Department shares regular information about impending supply issues and management plans with the NHS via networks in primary and secondary care and will liaise with relevant patient groups about issues affecting specific medicines, medical devices and equipment.
To ask the Secretary of State for Health if his Department will take steps in partnership with pharmaceutical companies to fund clinical trials to assess the effectiveness of low dose naltrexone in providing relief to patients with autoimmune diseases and central nervous system disorders.
To ask the Secretary of State for Health if his Department will take steps in partnership with pharmaceutical companies to fund clinical trials to assess the effectiveness of low dose naltrexone in providing relief to patients with autoimmune diseases and central nervous system disorders.
The Department's National Institute for Health Research (NIHR) manages the Efficacy and Mechanism Evaluation programme, which is funded by the Medical Research Council and the NIHR. University-based researchers can apply to this programme for funding for the evaluation of the clinical efficacy of treatments, including the use of low dose naltrexone. If evidence from such evaluations is promising, larger scale trials can follow.
The NIHR Clinical Research Network provides a single point of contact for industry studies, offers centralised and co-ordinated study feasibility assessment, and support with patient recruitment.
Adjournment debate on the availability of low dose naltrexone.
Adjournment debate on the availability of low dose naltrexone.
And may I, in the spirit of Christmas, thank the hon. Lady very much for the way in which she presented her case? It was quite clear from listening to her speech that she rightly felt very strongly about the issue on behalf of not only her constituents but people...
And may I, in the spirit of Christmas, thank the hon. Lady very much for the way in which she presented her case? It was quite clear from listening to her speech that she rightly felt very strongly about the issue on behalf of not only her constituents but people...
I am grateful to the hon. Lady for raising that point on behalf of her constituents. The short answer is that it is simply because there have been no clinical trials to assess the drug in its low-dosage levels, and so the conditions of the NHS, under the ways in...
I am grateful to the hon. Lady for raising that point on behalf of her constituents. The short answer is that it is simply because there have been no clinical trials to assess the drug in its low-dosage levels, and so the conditions of the NHS, under the ways in...
May I take this opportunity to thank the Minister for his very full and helpful reply?
May I take this opportunity to thank the Minister for his very full and helpful reply?
I begin by congratulating the hon. Member for Llanelli (Nia Griffith) on securing the debate and hope that by the end of my comments, particularly the last section, she will feel that there is a mechanism and a way forward that she will find helpful. Like her, I am well...
I begin by congratulating the hon. Member for Llanelli (Nia Griffith) on securing the debate and hope that by the end of my comments, particularly the last section, she will feel that there is a mechanism and a way forward that she will find helpful. Like her, I am well...
The Minister is being very clear in his exposition. The question that my constituents continually ask is why the NHS is not in the least bit interested in a treatment that is so cheap, costing about 50p a day, and appears to defer care costs into the bargain. A constituent...
The Minister is being very clear in his exposition. The question that my constituents continually ask is why the NHS is not in the least bit interested in a treatment that is so cheap, costing about 50p a day, and appears to defer care costs into the bargain. A constituent...
The hon. Lady is quite right. These people fear that if they change from one GP to another, or if people are less sympathetic towards this drug—obviously this is something that people have to be convinced about—they may well not be able to get hold of it. Unless there is...
The hon. Lady is quite right. These people fear that if they change from one GP to another, or if people are less sympathetic towards this drug—obviously this is something that people have to be convinced about—they may well not be able to get hold of it. Unless there is...
First, I want to make it clear that this debate is not about fighting for a very new and expensive drug. Campaigns about drugs are often brought to the attention of Parliament because a patient is fighting to be allowed to have a new and expensive treatment on the NHS....
First, I want to make it clear that this debate is not about fighting for a very new and expensive drug. Campaigns about drugs are often brought to the attention of Parliament because a patient is fighting to be allowed to have a new and expensive treatment on the NHS....
I congratulate the hon. Member for Llanelli (Nia Griffith) on securing this debate. I am sure that, like me, she has a number of constituents who are benefiting from this drug—I refer particularly to members of the Purbeck and Wareham multiple sclerosis group. It is so frustrating that they cannot...
I congratulate the hon. Member for Llanelli (Nia Griffith) on securing this debate. I am sure that, like me, she has a number of constituents who are benefiting from this drug—I refer particularly to members of the Purbeck and Wareham multiple sclerosis group. It is so frustrating that they cannot...
To ask the Secretary of State for the Home Department to what extent the drug naltrexone is used (a) in connection with probationary release of recidivist addict offenders and (b) to keep prisoners clean of opiates while they are in custody.
To ask the Secretary of State for the Home Department to what extent the drug naltrexone is used (a) in connection with probationary release of recidivist addict offenders and (b) to keep prisoners clean of opiates while they are in custody.
To ask the Secretary of State for Health what research she has commissioned on the use of naltrexone as a treatment for drug misusers; and if she will make a statement.
To ask the Secretary of State for Health what research she has commissioned on the use of naltrexone as a treatment for drug misusers; and if she will make a statement.
To ask the Secretary of State for Health, if his Department will conduct trials of the use of low-dose naltrexone in the treatment of multiple sclerosis; and if he will make a statement on its availability on the NHS; what trials have taken place of low dose Naltrexone (LDN) for...
To ask the Secretary of State for Health, if his Department will conduct trials of the use of low-dose naltrexone in the treatment of multiple sclerosis; and if he will make a statement on its availability on the NHS; what trials have taken place of low dose Naltrexone (LDN) for...
To ask the Secretary of State for the Home Department, how many prisoners received (a) methadone, (b) subutex and (c) naltraxone for substance misuse in the last month for which figures are available. - (Holding answer 24 June 2004).
To ask the Secretary of State for the Home Department, how many prisoners received (a) methadone, (b) subutex and (c) naltraxone for substance misuse in the last month for which figures are available. - (Holding answer 24 June 2004).